{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:42:39Z","timestamp":1791243759353,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["ATVB"],"published-print":{"date-parts":[[2000,7]]},"abstract":"<jats:p>\n            <jats:italic>Abstract<\/jats:italic>\n            \u2014Atherosclerosis involves a complex array of factors, including leukocyte adhesion and platelet vasoactive factors. Aspirin, which is used to prevent secondary complications of atherosclerosis, inhibits platelet production of thromboxane (Tx) A\n            <jats:sub>2<\/jats:sub>\n            . The actions of TxA\n            <jats:sub>2<\/jats:sub>\n            as well as of other arachidonic acid products, such as prostaglandin (PG) H\n            <jats:sub>2<\/jats:sub>\n            , PGF\n            <jats:sub>2\u03b1<\/jats:sub>\n            , hydroxyeicosatetraenoic acids, and isoprostanes, can be effectively antagonized by blocking thromboxane (TP) receptors. The purpose of this study was to determine the role of platelet-derived TxA\n            <jats:sub>2<\/jats:sub>\n            in atherosclerotic lesion development by comparing the effects of aspirin and the TP receptor antagonist S18886. The effect of 11 weeks of treatment with aspirin (30 mg \u00b7 kg\n            <jats:sup>\u22121<\/jats:sup>\n            \u00b7 d\n            <jats:sup>\u22121<\/jats:sup>\n            ) or S18886 (5 mg \u00b7 kg\n            <jats:sup>\u22121<\/jats:sup>\n            \u00b7 d\n            <jats:sup>\u22121<\/jats:sup>\n            ) on aortic root atherosclerotic lesions, serum levels of intercellular adhesion molecule-1 (ICAM-1), and the TxA\n            <jats:sub>2<\/jats:sub>\n            metabolite TxB\n            <jats:sub>2<\/jats:sub>\n            was determined in apolipoprotein E\u2013deficient mice at 21 weeks of age. Both treatments did not affect body or heart weight or serum cholesterol levels. Aspirin, to a greater extent than S18886, significantly decreased serum TxB\n            <jats:sub>2<\/jats:sub>\n            levels, indicating the greater efficacy of aspirin in preventing platelet synthesis of TxA\n            <jats:sub>2<\/jats:sub>\n            . S18886, but not aspirin, significantly decreased aortic root lesions as well as serum ICAM-1 levels. S18886 also prevented the increased expression of ICAM-1 in cultured human endothelial cells stimulated by the TP receptor agonist U46619. These results indicate that inhibition of platelet TxA\n            <jats:sub>2<\/jats:sub>\n            synthesis with aspirin has no significant effect on atherogenesis or adhesion molecule levels. The effects of S18886 suggest that blockade of TP receptors inhibits atherosclerosis by a mechanism independent of platelet-derived TxA\n            <jats:sub>2<\/jats:sub>\n            , perhaps by preventing the expression of adhesion molecules whose expression is stimulated by eicosanoids other than TxA\n            <jats:sub>2<\/jats:sub>\n            .\n          <\/jats:p>","DOI":"10.1161\/01.atv.20.7.1724","type":"journal-article","created":{"date-parts":[[2011,6,17]],"date-time":"2011-06-17T19:44:19Z","timestamp":1308339859000},"page":"1724-1728","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":189,"title":["The Thromboxane Receptor Antagonist S18886 but Not Aspirin Inhibits Atherogenesis in Apo E\u2013Deficient Mice"],"prefix":"10.1161","volume":"20","author":[{"given":"Antonio J.","family":"Cayatte","sequence":"first","affiliation":[{"name":"From the Vascular Biology Unit (A.J.C., Y.D., J.O.-K., R.A.C.), Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Mass, and Institut de Recherche Servier (G.L., T.J.V.), Suresnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Du","sequence":"additional","affiliation":[{"name":"From the Vascular Biology Unit (A.J.C., Y.D., J.O.-K., R.A.C.), Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Mass, and Institut de Recherche Servier (G.L., T.J.V.), Suresnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Oliver-Krasinski","sequence":"additional","affiliation":[{"name":"From the Vascular Biology Unit (A.J.C., Y.D., J.O.-K., R.A.C.), Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Mass, and Institut de Recherche Servier (G.L., T.J.V.), Suresnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Lavielle","sequence":"additional","affiliation":[{"name":"From the Vascular Biology Unit (A.J.C., Y.D., J.O.-K., R.A.C.), Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Mass, and Institut de Recherche Servier (G.L., T.J.V.), Suresnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony J.","family":"Verbeuren","sequence":"additional","affiliation":[{"name":"From the Vascular Biology Unit (A.J.C., Y.D., J.O.-K., R.A.C.), Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Mass, and Institut de Recherche Servier (G.L., T.J.V.), Suresnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Cohen","sequence":"additional","affiliation":[{"name":"From the Vascular Biology Unit (A.J.C., Y.D., J.O.-K., R.A.C.), Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Mass, and Institut de Recherche Servier (G.L., T.J.V.), Suresnes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(98)80028-3"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1996.00503.x"},{"key":"e_1_3_2_4_2","first-page":"H318","volume":"255","year":"1988","journal-title":"Am J Physiol"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.87.5.8491012"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(82)90159-9"},{"key":"e_1_3_2_7_2","unstructured":"Hollander W Kramsch DM Franzblau C Paddock J Colombo MA. Suppression of atheromatous fibrous plaque formation by antiproliferative and anti-inflammatory drugs. Circ Res . 1974;(suppl I):I-131\u2013I-141."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(79)90083-2"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901143400207"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-3278(96)90071-X"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-6980(88)90047-0"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/2685"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(96)00478-5"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00915886"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/atvb.17.11.2309"},{"key":"e_1_3_2_16_2","unstructured":"Verbeuren TJ Descombes JJ Simonet S Dubuffet T Lavielle G. The TP-receptor antagonist S 18886 unmasks vascular relaxation and potentiates the anti-platelet action of PGD 2 . Thromb Haemost . 1997;(suppl):693."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","unstructured":"Simonet S Descombes JJ Vallez MO Dubuffet T Lavielle T Verbeuren TJ. S 18886 a new thromboxane (TP)-receptor antagonist is the active isomer of S 18024 in all species except in the guinea-pig: In: Sinzinger H ed. Recent Advances in Prostaglandin Thromboxane and Leukotriene Research . New York NY: Plenum Press; 1998:173\u2013176.","DOI":"10.1007\/978-1-4899-1810-9_35"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(98)00220-0"},{"key":"e_1_3_2_19_2","first-page":"277","volume":"13","year":"1999","journal-title":"Fund Clin Pharmacol"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(87)90202-4"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4652(199606)167:3<477::AID-JCP12>3.0.CO;2-1"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI3985"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199505000-00010"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)53294-4"}],"container-title":["Arteriosclerosis, Thrombosis, and Vascular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.ATV.20.7.1724","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T18:59:35Z","timestamp":1715021975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.ATV.20.7.1724"}},"subtitle":["Evidence That Eicosanoids Other Than Thromboxane Contribute to Atherosclerosis"],"short-title":[],"issued":{"date-parts":[[2000,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2000,7]]}},"alternative-id":["10.1161\/01.ATV.20.7.1724"],"URL":"https:\/\/doi.org\/10.1161\/01.atv.20.7.1724","relation":{},"ISSN":["1079-5642","1524-4636"],"issn-type":[{"value":"1079-5642","type":"print"},{"value":"1524-4636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,7]]},"assertion":[{"value":"2000-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-02-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}